Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan

Research output: Contribution to journalArticle

Abstract

Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.

Original languageEnglish
Pages (from-to)S785-S788
JournalJournal of Cancer Research and Therapeutics
Volume14
Issue number10
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Taiwan
Prostate
Hormones
Etoposide
Cisplatin
Transurethral Resection of Prostate
Androgens
Prostatic Neoplasms
Adenocarcinoma
Drug Therapy
Neoplasms

Keywords

  • Large cell
  • neuroendocrine tumor
  • transurethral resection of the prostate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{55f16344362f449dba508d44233829ce,
title = "Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan",
abstract = "Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.",
keywords = "Large cell, neuroendocrine tumor, transurethral resection of the prostate",
author = "Tzou, {Kai Yi} and Cheng, {Wei Hung} and Lee, {Wei Hwa} and Ho, {Chen Hsun}",
year = "2018",
month = "1",
day = "1",
doi = "10.4103/0973-1482.180685",
language = "English",
volume = "14",
pages = "S785--S788",
journal = "Journal of Cancer Research and Therapeutics",
issn = "0973-1482",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "10",

}

TY - JOUR

T1 - Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient

T2 - A case report from Taiwan

AU - Tzou, Kai Yi

AU - Cheng, Wei Hung

AU - Lee, Wei Hwa

AU - Ho, Chen Hsun

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.

AB - Large cell neuroendocrine carcinoma (LCNEC) of the prostate is extremely rare. Previously reported cases in the literature were almost exclusively developed in men receiving androgen deprivation therapy for prostate adenocarcinoma. We herein present a case of de novo LCNEC: A 66-year-old male was incidentally diagnosed as LCNEC after he underwent transurethral resection of prostate. The stage was T4N1M1. Therefore, the patient was treated with 6 cycles of cisplatin and etoposide in the following 6 months, which achieved a partial remission. He gave up the chance to eradicate the residual mass. Three months later, the tumor progressed rapidly. In conclusion, LCNEC is a rare prostate cancer. Our experience shows that chemotherapy with etoposide and cisplatin is effective to achieve a significant remission. However, LCNEC is highly malignant in nature, postchemotherapy surgery for the residual mass should be considered.

KW - Large cell

KW - neuroendocrine tumor

KW - transurethral resection of the prostate

UR - http://www.scopus.com/inward/record.url?scp=85054041763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054041763&partnerID=8YFLogxK

U2 - 10.4103/0973-1482.180685

DO - 10.4103/0973-1482.180685

M3 - Article

AN - SCOPUS:85054041763

VL - 14

SP - S785-S788

JO - Journal of Cancer Research and Therapeutics

JF - Journal of Cancer Research and Therapeutics

SN - 0973-1482

IS - 10

ER -